Fig. 3.

Probabilistic sensitivity analysis for ezetimibe, evolocumab, alirocumab, icosapent ethyl, and fenofibrate in combination with statins for primary (A) and secondary (B) cardiovascular prevention. Input parameters displayed in Table 1 were varied by their confidence intervals and distribution; 1000 simulations of this probabilistic sensitivity analysis are visualised in this Figure. The grey line illustrates the English NHS’ upper willingness-to-pay threshold of £30,000 per QALY. Lipid-lowering drugs are presented as cholesterol- and triglyceride-lowering according to guideline recommendations [11]. QALYs and costs presented for the average person simulated in the model. Costs in 2021 Great Britain Pounds (£). ICER incremental cost-effectiveness ratio, NHS National Health Service, QALY quality-adjusted life year